Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Tarlatamab
Synonyms
Therapy Description

Imdelltra (tarlatamab) is a bispecific antibody that targets CD3 on T-cells and delta-like protein 3 (DLL3) expressed by tumor cells, which may lead to cytotoxic killing of Dll3-expressing tumor cells (PMID: 31215500). Imdelltra (tarlatamab) is FDA-approved for use in patients with extensive stage small cell lung cancer who progressed on or after platinum-based chemotherapy (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Tarlatamab Imdelltra AMG 757|AMG757|AMG-757|tarlatamab-dlle CD3 Antibody 111 DLL3 Antibody 9 Imdelltra (tarlatamab) is a bispecific antibody that targets CD3 on T-cells and delta-like protein 3 (DLL3) expressed by tumor cells, which may lead to cytotoxic killing of Dll3-expressing tumor cells (PMID: 31215500). Imdelltra (tarlatamab) is FDA-approved for use in patients with extensive stage small cell lung cancer who progressed on or after platinum-based chemotherapy (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06937905 Phase III Tarlatamab Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs) (TARLANEC) Not yet recruiting FRA 0
NCT05060016 Phase II Tarlatamab A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) Active, not recruiting USA | POL | NLD | ITA | GRC | GBR | FRA | ESP | DNK | DEU | CHE | BEL | AUT 5
NCT06117774 Phase III Tarlatamab Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) (DeLLphi-306) Recruiting USA | TUR | SWE | ROU | POL | ITA | GRC | GBR | FRA | ESP | DEU | CHE | BRA | BGR | BEL | AUT | AUS | ARG 9
NCT05740566 Phase III Lurbinectedin Topotecan Amrubicin Tarlatamab Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) Active, not recruiting USA | TUR | ROU | POL | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG 8
NCT06745323 Phase II Tarlatamab A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC (DeLLphi-309) Recruiting USA | TUR | GRC | ESP | CHE | BRA | AUS | ARG 3
NCT06776250 Phase II Tarlatamab Study of How Safe and Effective Tarlatamab is in Brain Cancers Not yet recruiting CAN 0
NCT06814496 Phase Ib/II Tarlatamab Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Not yet recruiting USA 0
NCT06788938 Phase II Tarlatamab Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms Recruiting USA 0
NCT04702737 Phase I Tarlatamab A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer Completed USA | NLD | GBR | FRA | ESP | BEL | AUT | AUS 1
NCT03319940 Phase I Tarlatamab Study Evaluating Safety, Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer Active, not recruiting USA | POL | NLD | GBR | FRA | ESP | DEU | CHE | AUT | AUS 3
NCT06598306 Phase I Tarlatamab Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) (DeLLphi-308) Recruiting USA | TUR | POL | ESP | DEU | CHE | BEL | AUS 1


Additional content available in Icon for CKB-BoostCKB BOOST